Pharmacological and Clinical Evaluation of Telotristat Ethyl: A Peripheral Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome / 中国药师

ABSTRACT

Telotristat ethyl is a peripheral tryptophan hydroxylase (TPH) inhibitor for the treatment of carcinoid syndrome. Telotristat ethyl inhibits TPH,thereby reducing the production of serotoin(5-HT) and the daily bowel movement. Pharmacology, pharmacokinetics,clinical studies and safety of telotristat ethyl were reviewed in the paper. Telotristat ethyl has become a novel treatment option for carcinoid syndrome patients. Telotristat ethyl is well tolerated with low incidence of side effects.